JP2002525327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002525327A5 JP2002525327A5 JP2000571923A JP2000571923A JP2002525327A5 JP 2002525327 A5 JP2002525327 A5 JP 2002525327A5 JP 2000571923 A JP2000571923 A JP 2000571923A JP 2000571923 A JP2000571923 A JP 2000571923A JP 2002525327 A5 JP2002525327 A5 JP 2002525327A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- receptor antagonist
- antagonist
- use according
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 8
- 229940044551 receptor antagonist Drugs 0.000 description 8
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 208000018238 Primary Headache disease Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical group C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 2
- 229960004704 dihydroergotamine Drugs 0.000 description 2
- 125000002250 eicosanoid group Chemical group 0.000 description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical group C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
- 229960005417 ketanserin Drugs 0.000 description 2
- 229960005254 naratriptan Drugs 0.000 description 2
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 229940127293 prostanoid Drugs 0.000 description 2
- 239000004003 serotonin 1D agonist Substances 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical group CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960001360 zolmitriptan Drugs 0.000 description 2
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- -1 ergot derivatives Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9720270.9A GB9720270D0 (en) | 1997-09-25 | 1997-09-25 | Medicaments for the treatment of migraine |
| PCT/GB1998/002895 WO2000018405A1 (en) | 1997-09-25 | 1998-09-25 | Use of prostanoid antagonists for the treatment of primary headache disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009235310A Division JP2010047583A (ja) | 2009-10-09 | 2009-10-09 | 原発性頭痛障害の治療のためのプロスタノイドアンタゴニストの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002525327A JP2002525327A (ja) | 2002-08-13 |
| JP2002525327A5 true JP2002525327A5 (https=) | 2006-01-05 |
Family
ID=26312305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000571923A Pending JP2002525327A (ja) | 1997-09-25 | 1998-09-25 | 原発性頭痛障害の治療のためのプロスタノイドアンタゴニストの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8513027B2 (https=) |
| EP (1) | EP1115404B1 (https=) |
| JP (1) | JP2002525327A (https=) |
| AT (1) | ATE257707T1 (https=) |
| AU (1) | AU757265B2 (https=) |
| CA (1) | CA2345248C (https=) |
| DE (1) | DE69821142T2 (https=) |
| DK (1) | DK1115404T3 (https=) |
| ES (1) | ES2213914T3 (https=) |
| GB (2) | GB9720270D0 (https=) |
| PT (1) | PT1115404E (https=) |
| WO (1) | WO2000018405A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| CA2402099C (en) * | 2000-03-24 | 2011-04-26 | Pharmagene Laboratories Ltd. | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
| JP2005511562A (ja) * | 2001-10-31 | 2005-04-28 | メディカル リサーチ カウンシル | 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト |
| RU2004126093A (ru) * | 2002-02-26 | 2005-04-10 | Орто-Макнейл Фармасьютикал, Инк. (Us) | Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20150126573A1 (en) | 2012-05-09 | 2015-05-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2028805B (en) | 1978-07-11 | 1982-11-03 | Glaxo Group Ltd | Prostanoid compounds |
| IL62734A (en) | 1980-04-30 | 1985-10-31 | Glaxo Group Ltd | Aminocyclopentane alkenoic acids and esters,their preparation and pharmaceutical formulations |
| US4839384A (en) | 1988-10-07 | 1989-06-13 | E. R. Squibb & Sons, Inc. | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist |
| JP3222891B2 (ja) | 1991-05-03 | 2001-10-29 | ジー．ディー．サール アンド カンパニー | 置換ベンゾオキサゼピン化合物、医薬品組成物およびその使用方法 |
| US5182272A (en) | 1991-05-03 | 1993-01-26 | G. D. Searle & Co. | 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain |
| US5212169A (en) | 1991-10-31 | 1993-05-18 | G. D. Searle & Co. | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain |
| AU2669992A (en) | 1991-11-05 | 1993-06-07 | G.D. Searle & Co. | 10-acyl-dibenz(b,f) (1,4)-oxazepines and their thiazepines analo gues useful as prostaglandin antagonists |
| AU3143593A (en) | 1991-12-20 | 1993-07-28 | G.D. Searle & Co. | Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin E2 antagonists |
| US5266571A (en) | 1992-01-09 | 1993-11-30 | Amer Moh Samir | Treatment of hemorrhoids with 5-HT2 antagonists |
| US5395932A (en) | 1993-04-30 | 1995-03-07 | G. D. Searle & Co. | 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| US5488046A (en) | 1993-11-03 | 1996-01-30 | G. D. Searle & Co. | Carbamic acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| CN1046714C (zh) | 1993-12-20 | 1999-11-24 | 藤泽药品工业株式会社 | 二芳基噁唑衍生物及其制法、应用和药物组合物 |
| TW282456B (https=) | 1994-03-10 | 1996-08-01 | Fujisawa Yakusin Kogyo Kk | |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| AUPO713297A0 (en) | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| US20030158240A1 (en) | 1998-09-25 | 2003-08-21 | Pharmagene Laboratories Limited | Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment |
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| EP1071648A2 (en) | 1998-03-13 | 2001-01-31 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| JP2002527393A (ja) | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨吸収阻害方法 |
| AU6836200A (en) | 1999-08-10 | 2001-03-05 | Glaxo Group Limited | Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer |
| US20080275095A1 (en) | 2004-05-03 | 2008-11-06 | Astellas Pharma Inc. | Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases |
-
1997
- 1997-09-25 GB GBGB9720270.9A patent/GB9720270D0/en not_active Ceased
-
1998
- 1998-09-25 PT PT98944111T patent/PT1115404E/pt unknown
- 1998-09-25 DK DK98944111T patent/DK1115404T3/da active
- 1998-09-25 EP EP98944111A patent/EP1115404B1/en not_active Expired - Lifetime
- 1998-09-25 GB GB9820936A patent/GB2341799B/en not_active Expired - Fee Related
- 1998-09-25 AT AT98944111T patent/ATE257707T1/de active
- 1998-09-25 WO PCT/GB1998/002895 patent/WO2000018405A1/en not_active Ceased
- 1998-09-25 JP JP2000571923A patent/JP2002525327A/ja active Pending
- 1998-09-25 DE DE69821142T patent/DE69821142T2/de not_active Expired - Lifetime
- 1998-09-25 CA CA002345248A patent/CA2345248C/en not_active Expired - Fee Related
- 1998-09-25 ES ES98944111T patent/ES2213914T3/es not_active Expired - Lifetime
- 1998-09-25 AU AU91776/98A patent/AU757265B2/en not_active Ceased
-
2007
- 2007-10-30 US US11/976,945 patent/US8513027B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL101162A (en) | Pharmaceutical composition for oral administration comprising an indole derivative | |
| MXPA03000548A (es) | Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica. | |
| CA2229597A1 (en) | Oral fast-dissolving compositions for dopamine agonists | |
| WO2002004418A2 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
| WO2000010551A3 (en) | Methods of using and compositions comprising dopamine reuptake inhibitors | |
| EP1027011A4 (en) | ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING | |
| WO2002003988A2 (en) | Use of substituted indole compounds for treating neuropeptide y-related conditions | |
| AU4818000A (en) | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands | |
| DK1623703T3 (da) | Hydrocodonformuleringer med kontrolleret frigivelse | |
| AU2001285451A1 (en) | 2,4-substituted pyridine derivatives | |
| IL149496A (en) | Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract | |
| WO2002003986A2 (en) | Use of substituted indole compounds for treating breast disorders | |
| WO2002003990A2 (en) | Use of substituted insole compounds for treating excessive intraocular pressure | |
| JP2005503382A5 (https=) | ||
| JP2002525327A5 (https=) | ||
| Davidson et al. | Bupropion sustained release: a therapeutic overview | |
| IT1313585B1 (it) | Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. | |
| WO2004096118A3 (en) | Composition for improving cognition and memory | |
| CA2221091A1 (en) | Estrogen agonist/antagonists treatment of atherosclerosis | |
| EA200100089A1 (ru) | Предотвращение рецидива мигрени | |
| CA2135179C (en) | Pharmaceutical compositions of alkylsulphonamides 5ht1 agonists for rectal administration | |
| EP0656209B1 (en) | Melatonin derivatives for use in treating desynchronization disorders | |
| BR0015172A (pt) | Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno | |
| EP0655243A2 (en) | Melatonin derivatives for use in treating sleep disorders | |
| US20020099059A1 (en) | Combination therapy for the treatment of migraine |